Divergent Synthesis of (+)-Kuhistanicaol G and (+)-Ferutinin through the Common Intermediate Jaeschkeanadiol
Synthesis · 14.08.2026 · 58 (22) · 2629-2638
DOI: 10.1055/a-2927-3974 ↗Kurz gefasst
Fachartikel in der Zeitschrift Synthesis, erschienen am 14.08.2026. Verfasst von Eric C. Wang und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Motivated by the potent anticancer activity of kuhistanicaol G and ferutinin against the pancreatic cancer cell line PANC-1, we report the total syntheses of (+)-kuhistanicaol G and (+)-ferutinin. Our divergent synthetic strategy proceeds through the common intermediate jaeschkeanadiol and features several key transformations, including tandem radical addition/allylation, chelation-controlled nucleophilic addition, and Chugaev elimination. This work establishes a robust platform for the synthesis of structurally diverse analogues of (+)-kuhistanicaol G and (+)-ferutinin, as well as mechanistic chemical probes, thereby facilitating the future development of natural product-derived therapeutics for pancreatic cancer.
Zitieren
APA
Wang, E. C., Shin, I., & Hong, J. (2026). Divergent Synthesis of (+)-Kuhistanicaol G and (+)-Ferutinin through the Common Intermediate Jaeschkeanadiol. Synthesis, 58(22), 2629-2638. https://doi.org/10.1055/a-2927-3974
Vancouver
Wang EC, Shin I, Hong J. Divergent Synthesis of (+)-Kuhistanicaol G and (+)-Ferutinin through the Common Intermediate Jaeschkeanadiol. Synthesis. 2026;58(22):2629-2638. doi:10.1055/a-2927-3974
BibTeX
@article{Wang2026,
author = {Wang, Eric C. and Shin, Iljin and Hong, Jiyong},
title = {Divergent Synthesis of (+)-Kuhistanicaol G and (+)-Ferutinin through the Common Intermediate Jaeschkeanadiol},
journal = {Synthesis},
year = {2026},
volume = {58},
number = {22},
pages = {2629--2638},
doi = {10.1055/a-2927-3974}
}
EUVIMED